Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q20706886> ?p ?o }
Showing triples 1 to 39 of
39
with 100 triples per page.
- Q20706886 subject Q8210698.
- Q20706886 subject Q8732553.
- Q20706886 subject Q8790228.
- Q20706886 abstract "MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD). It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake, and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors. As of May 2015, MIN-117 is in phase II clinical trials for MDD.".
- Q20706886 iupacName "(2S)-1-[4-(3,4-Dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol".
- Q20706886 thumbnail MIN-117.svg?width=300.
- Q20706886 wikiPageExternalLink Minerva_Investor_Presentation_-_March_2015.pdf.
- Q20706886 wikiPageExternalLink 800037483.
- Q20706886 wikiPageExternalLink science.
- Q20706886 wikiPageWikiLink Q14891424.
- Q20706886 wikiPageWikiLink Q167934.
- Q20706886 wikiPageWikiLink Q170304.
- Q20706886 wikiPageWikiLink Q17710475.
- Q20706886 wikiPageWikiLink Q17710494.
- Q20706886 wikiPageWikiLink Q18387287.
- Q20706886 wikiPageWikiLink Q238509.
- Q20706886 wikiPageWikiLink Q30612.
- Q20706886 wikiPageWikiLink Q3563148.
- Q20706886 wikiPageWikiLink Q408588.
- Q20706886 wikiPageWikiLink Q410943.
- Q20706886 wikiPageWikiLink Q42844.
- Q20706886 wikiPageWikiLink Q4859664.
- Q20706886 wikiPageWikiLink Q7180990.
- Q20706886 wikiPageWikiLink Q76560.
- Q20706886 wikiPageWikiLink Q7693930.
- Q20706886 wikiPageWikiLink Q8210698.
- Q20706886 wikiPageWikiLink Q8732553.
- Q20706886 wikiPageWikiLink Q8790228.
- Q20706886 wikiPageWikiLink Q899107.
- Q20706886 wikiPageWikiLink Q910028.
- Q20706886 iupacName "-1".
- Q20706886 type ChemicalSubstance.
- Q20706886 type Drug.
- Q20706886 type ChemicalObject.
- Q20706886 type Thing.
- Q20706886 type Q8386.
- Q20706886 comment "MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD). It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake, and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors. As of May 2015, MIN-117 is in phase II clinical trials for MDD.".
- Q20706886 label "MIN-117".
- Q20706886 depiction MIN-117.svg.